Yoshihisa Nakagawa
A5079494440- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Lipoproteins and Cardiovascular Health
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac pacing and defibrillation studies
- Venous Thromboembolism Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Infective Endocarditis Diagnosis and Management
- Cerebrovascular and Carotid Artery Diseases
- Peripheral Artery Disease Management
- Aortic aneurysm repair treatments
- Pneumonia and Respiratory Infections
- Coronary Artery Anomalies
- Aortic Disease and Treatment Approaches
- Acute Ischemic Stroke Management
- Pericarditis and Cardiac Tamponade
- Aortic Thrombus and Embolism
Shiga University of Medical Science Hospital
2019-2025
Shiga University of Medical Science
2019-2025
Tenri Hospital
2015-2024
Ogaki Municipal Hospital
2011-2023
Saga University
2023
University of Oxford
2023
Kyoto University
2007-2021
Shiga University
2019-2021
Clinical Research Consortium
2021
Lenox Hill Hospital
2021
<h3>Importance</h3> Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. <h3>Objective</h3> To test the hypothesis of noninferiority 1 month DAPT compared standard 12 months for composite end point cardiovascular and bleeding events. <h3>Design, Setting, Participants</h3> Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan...
Coronary-artery stents are known to reduce rates of restenosis after coronary angioplasty, but it is uncertain how long this benefit maintained.
Background— The influences of antiplatelet therapy discontinuation on the risk stent thrombosis and long-term clinical outcomes after drug-eluting implantation have not yet been addressed adequately. Methods Results— In an observational study in Japan, 2-year were assessed 10 778 patients undergoing sirolimus-eluting implantation. Data status during follow-up collected prospectively. Incidences definite 0.34% at 30 days, 0.54% 1 year, 0.77% 2 years. Thienopyridine use was maintained 97%,...
There is a scarcity of long-term data from large-scale drug-eluting stent registries with large enough sample to evaluate low-frequency events such as thrombosis (ST).Five-year outcomes were evaluated in 12 812 consecutive patients undergoing sirolimus-eluting (SES) implantation the j-Cypher registry. Cumulative incidence definite ST was low (30 day, 0.3%; 1 year, 0.6%; and 5 years, 1.6%). However, late very continued occur without attenuation up years after (0.26%/y). target lesion...
<h3>Importance</h3> Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute syndrome (ACS). <h3>Objective</h3> To test the hypothesis of noninferiority 1 to 2 months DAPT compared 12 for a composite end point cardiovascular and bleeding events ACS. <h3>Design, Setting, Participants</h3> This multicenter, open-label, randomized clinical trial enrolled 4169 ACS who underwent...
Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease on the basis of several previous "more versus less statins" trials. However, no clear evidence more statins has been established an Asian population. In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese stable coronary artery who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were...
Prediction of thrombotic and bleeding risk is important to optimize antithrombotic therapy after percutaneous coronary intervention.We developed the prediction rules for events separately in Japanese patients. Derivation validation cohorts consisted 4778 patients from CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study Kyoto) registry cohort 2 4669 RESET (Randomized Evaluation Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial) NEXT (Nobori Biolimus-Eluting Xience/Promus...
Background: Despite recommendations in the guidelines and consensus documents, there has been no randomized controlled trial evaluating oral anticoagulation (OAC) alone without antiplatelet therapy (APT) patients with atrial fibrillation stable coronary artery disease beyond 1 year after stenting. Methods: This study was a prospective, multicenter, open-label, noninferiority comparing OAC to combined single APT among stenting 1:1 randomization fashion. The primary end point composite of...
The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with coronary syndrome the setting optimal medical therapy remains unknown. REAL-CAD (Randomized Evaluation Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin Coronary Artery Disease) study is a prospective, multicenter, randomized trial high-dose (pitavastatin 4 mg/day) low-dose 1 statin 12 118 syndrome. primary end point was composite cardiovascular death, nonfatal...
Recently, long-term constriction of the vessel has been suggested as an alternative mechanism restenosis after coronary angioplasty.To understand remodeling human arteries undergoing angioplasty or atherectomy, serial intravascular ultrasonographic examinations were performed at preintervention and postintervention 24 hours, 1 month, 6 months. Complete data obtained in 61 lesions (balloon angioplasty, 35 lesions; directional 26 lesions). Lumen area improved from 6.81+/-2.24 mm2 intervention...
Background — Although coronary stents have been proved effective in reducing clinical cardiac events for up to 3 5 years, longer term and angiographic outcomes not yet fully clarified. Methods Results To evaluate (7 11 years) outcome, follow-up information was analyzed 405 patients with successful stenting native arteries. Primary or secondary stabilization, which defined as freedom from death, artery bypass grafting, target lesion-percutaneous intervention (TL-PCI) during the 14 months...
NEXT (NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial) was designed for evaluating the noninferiority of a biolimus-eluting stent (BES) relative to an everolimus-eluting (EES) in terms target lesion revascularization (TLR) at 1 year.Efficacy and safety data comparing biodegradable polymer BES with durable cobalt-chromium EES are currently limited.The trial is prospective, multicenter, randomized, open-label, EES. Between May October 2011, 3,235 patients were...
<b>Objective</b> To evaluate the relation of symptom onset to balloon time and door with long term clinical outcome in patients ST segment elevation myocardial infarction (STEMI) having primary percutaneous coronary intervention. <b>Design</b> Observation large cohort acute infarction. <b>Setting</b> 26 tertiary hospitals Japan. <b>Participants</b> 3391 STEMI who had intervention within 24 hours onset. <b>Main measures</b> Composite death congestive heart failure, compared by time....
Background— Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, no evaluating target-lesion revascularization. Methods Results— Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting Trial is prospective multicenter open-label EES with SES in Japan. The noninferiority relative to terms From February July 2010, 3197 patients were randomly...
Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize definition of HBR, which was arbitrarily defined as a 3 or 5 bleeding ≥4% at 1-year. However, prevalence and expected event rate HBR patients by ARC-HBR criteria are currently unknown in real-world percutaneous coronary intervention practice.We applied CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study Kyoto) registry cohort-2, multicenter that enrolled 13 058...
Background: There is a scarcity of reports on the clinical characteristics and management practice in contemporary all-comer patients with acute decompensated heart failure (ADHF).
There is a paucity of data on the management and prognosis cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal strategies.Methods Results:The COMMAND VTE Registry multicenter registry enrolling 3,027 consecutive acute symptomatic patients in Japan between 2010 2014. We divided entire cohort into 3 groups: active cancer (n=695, 23%), history (n=243, 8%), no (n=2089, 69%). The rate anticoagulation discontinuation was higher with (43.5%, 27.0%, respectively, at...
Abstract The high controlling nutritional status (CONUT) score that represents poor has been acknowledged to have prognostic implications in chronic heart failure. We aimed investigate its role acute decompensated failure (ADHF). Using the data from an multicenter registry enrolled 4056 consecutive patients hospitalized for ADHF Japan between 2014 and 2016, we analyzed 2466 whom on components of CONUT at hospital presentation were available. decrease lymphocyte count total cholesterol was...